Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Read also

Takeda

Takeda walks away from cell therapy in priority U-turn

Taysha Says

Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome

Intravitreal Injection of Retinal Progenitor

Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy

Mercury Bio

Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein